×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Gastric Cancer

Brielle Urciuoli
Patients with advanced gastric cancer tend to use their health care resources more often and have a worse quality of life than those without the disease
Silas Inman
Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
Jason Harris
Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.
Gina Columbus
Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.
Wayne Kuznar
Surgical palliation improved quality of live and solid food intake in patients with certain types of gastric cancer, according to a recent study.
Silas Inman
A recent study found that Opdivo improves survival in patients with gastric or gastroesophageal junction (GEJ) cancer. 
Laura Panjwani
The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy. 
Debu Tripathy, MD
Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.
Erin Moore
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Arlene Weintraub
In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other